Tranilast

SIGMA/T0318 - ≥98% (HPLC), powder

Synonym: 2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid; 3,4-DAA; N-(3,4-Dimethoxycinnamoyl)anthranilic acid; Rizaben; SB-252218

CAS Number: 53902-12-8
Empirical Formula (Hill Notation): C₁₈H₁₇NO₅
Molecular Weight: 327.33
MDL Number: MFCD00864787
Linear Formula: C₁₈H₁₇NO₅
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-T0318-10MG	10 mg	$210.00 1/EA	Add To Favorites
45-T0318-50MG	50 mg	$780.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts T0318-50MG.

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
InChI key	NZHGWWWHIYHZNX-CSKARUKUSA-N
mp	166.2-168.2 °C (lit.)
originator	Kissei
Quality Level	100
SMILES string	COc1ccc(C=CC(=O)Nc2ccccc2C(O)=O)cc1OC
solubility	DMSO: >10 mg/mL
	H₂O: insoluble
storage temp.	2-8°C

Application:	The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.
Biochem/physiol Actions:	Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).
Biochem/physiol Actions:	Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing T_H1-mediated autoimmune diseases.
Biochem/physiol Actions:	Tranilast is an anti-asthma drug, which inhibits LTC₄ and PGE₂ formation in stimulated monocytes, inhibits mast cell degranulation, and inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro.
Features and Benefits:	This compound was developed by Kissei . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	10, 50 mg in glass bottle

Symbol	GHS07
Signal word	Warning
Hazard statements	H302
Hazard Codes	Xn
Risk Statements	22
Safety Statements	26-36
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3

Purity	≥98% (HPLC)
mp	166.2-168.2 °C (lit.)
Storage Temp.	2-8°C
UNSPSC	41106500

To Order From a Quote